

Please type a plus sign (+) inside this box → +

PTO/SB/05 (03-01)
Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.UTILITY
PATENT APPLICATION
TRANSMITTAL

(Only for new nonprovisional applications under 37 C.F.R. 1.53(b))

Attorney Docket No. PH-7087-A

First Inventor Priestley et al

Title NOVEL LACTAM INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE

Express Mail Label No. EV000875667US

APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents.		ADDRESS TO: Assistant Commissioner for Patents Box Patent Application Washington, DC 20231		
<p>1. <input checked="" type="checkbox"/> Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original and a duplicate for fee processing)</p> <p>2. <input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.</p> <p>3. <input checked="" type="checkbox"/> Specification [Total Pages 131] (preferred arrangement set forth below) - Descriptive title of the Invention - Cross Reference to Related Applications - Statement Regarding Fed sponsored R & D - Reference to sequence listing, a table, or a computer program listing appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure</p> <p>4. <input type="checkbox"/> Drawing(s) (35 U.S.C. 113) [Total Sheets 1]</p> <p>5. Oath or Declaration [Total Pages 1] a. <input type="checkbox"/> Newly executed (original or copy) b. <input checked="" type="checkbox"/> Copy from a prior application (37 CFR 1.63 (d)) (for a continuation/divisional with Box 18 completed) i. <input type="checkbox"/> DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).</p> <p>6. <input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76</p>		<p>7. <input type="checkbox"/> CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)</p> <p>8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. <input checked="" type="checkbox"/> Computer Readable Form (CRF) b. Specification Sequence Listing on: i. <input type="checkbox"/> CD-ROM or CD-R (2 copies); or ii. <input checked="" type="checkbox"/> paper c. <input checked="" type="checkbox"/> Statements verifying identity of above copies</p> <p>ACCOMPANYING APPLICATIONS PARTS</p> <p>9. <input type="checkbox"/> Assignment Papers (cover sheet & document(s)) 10. <input type="checkbox"/> 37 C.F.R. §3.73(b) Statement <input checked="" type="checkbox"/> Power of (when there is an assignee) Attorney</p> <p>11. <input type="checkbox"/> English Translation Document (if applicable)</p> <p>12. <input type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations</p> <p>13. <input checked="" type="checkbox"/> Preliminary Amendment</p> <p>14. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) (Should be specifically itemized)</p> <p>15. <input type="checkbox"/> Certified Copy of Priority Document(s) (if foreign priority is claimed)</p> <p>16. <input type="checkbox"/> Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.</p> <p>17. <input type="checkbox"/> Other:</p>		
<p>18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:</p> <p><input type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input checked="" type="checkbox"/> Continuation-in-part (CIP) of prior application No: 09 / 626,286 Prior application information: Examiner D. Lukton Group / Art Unit: 1653</p> <p>For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.</p>				
17. CORRESPONDENCE ADDRESS				
<input checked="" type="checkbox"/> Customer Number or Bar Code Label		24348 PATENT TRADEMARK OFFICE	or <input type="checkbox"/> Correspondence address below	
Name				
Address				
City	State	Zip Code		
Country	Telephone	Fax		
Name (Print/Type)	Scott K. Larsen		Registration No. (Attorney/Agent)	38,532
Signature			Date	06 December 2001

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231

FEE TRANSMITTAL for FY 2001

Patent fees are subject to annual revision.

EXPRESS MAIL NO.: EV000875667 US
DATE: DECEMBER 6, 2001

Complete if Known	
Application Number	Unknown
Filing Date	December 6, 2001
First Named Inventor	Priestley et al
Examiner Name	D. Lukton
Group / Art Unit	1653

TOTAL AMOUNT OF PAYMENT (\$ 848.00

Attorney Docket No. PH-7087-A

METHOD OF PAYMENT (check one)

1. The Commissioner is hereby authorized to charge indicated fees and credit any over payments to:

Deposit Account Number **023850**

Deposit Account Name **Bristol-Myers Squibb Pharma Company**

Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17

Applicant claims small entity status. See 37 CFR 1.27

2. Payment Enclosed:
 Check Credit card Money Order Other

FEE CALCULATION

1. BASIC FILING FEE

Large Entity	Small Entity	Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
101	740	201	355	Utility filing fee	740.00		
106	330	206	160	Design filing fee			
107	510	207	245	Plant filing fee			
108	740	208	355	Reissue filing fee			
114	160	214	75	Provisional filing fee			

SUBTOTAL (1)

(\$ 740.00)

2. EXTRA CLAIM FEES

Total Claims	26	-20**	=	6	X	18	=	108	Extra Claims	Fee from below	Fee Paid
Independent Claims				!Undefined Bookmark, TEXT1 31	X		=	0			
Multiple Dependent	1	-3**	=		X		=	0			

Large Entity	Small Entity	Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description
103	18	203	9	Claims in excess of 20		
102	84	202	40	Independent claims in excess of 3		
104	280	204	135	Multiple dependent claim, if not paid		
109	84	209	40	** Reissue independent claims over original patent		
110	18	210	9	** Reissue claims in excess of 20 and over original patent		

SUBTOTAL (2)

(\$ 108.00)

3. ADDITIONAL FEES

Large Entity	Entity	Small Entity	Entity	Fee Description	Fee Paid	
105	130	205	65	Surcharge - late filing fee or oath		
127	50	227	25	Surcharge - late provisional filing fee or cover sheet		
139	130	139	130	Non-English specification		
147	2,520	147	2,520	For filing a request for ex parte reexamination		
112	920*	112	920*	Requesting publication of SIR prior to Examiner action		
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action		
115	110	215	55	Extension for reply within first month		
116	400	216	195	Extension for reply within second month		
117	920	217	445	Extension for reply within third month		
118	1,440	218	695	Extension for reply within fourth month		
128	1,960	228	945	Extension for reply within fifth month		
119	310	219	155	Notice of Appeal		
120	310	220	155	Filing a brief in support of an appeal		
121	270	221	135	Request for oral hearing		
138	1,510	138	1,510	Petition to institute a public use proceeding		
140	110	240	55	Petition to revive – unavoidable		
141	1,240	241	620	Petition to revive – unintentional		
142	1,240	242	620	Utility issue fee (or reissue)		
143	440	243	220	Design issue fee		
144	600	244	300	Plant issue fee		
122	130	122	130	Petitions to the Commissioner		
123	130	123	50	Petitions related to provisional applications		
126	240	126	240	Submission of Information Disclosure Stmt		
581	40	581	40	Recording each patent assignment per property (times number of properties)		
146	710	246	355	Filing a submission after final rejection (37 CFR § 1.129(a))		
149	710	249	355	For each additional invention to be examined (37 CFR § 1.129(b))		
179	(RCE)	710	279	355	Request for Continued Examination	
169	900	169	900	Request for expedited examination of a design application		

Other fee (specify)

*Reduced by Basic Filing Fee Paid


SUBTOTAL (3)

(\$)

**or number previously paid, if greater; For Reissues, see above

SUBMITTED BY

Complete (if applicable)

Name (Print/Type)	Scott K. Larsen	Registration No. Attorney/Agent)	38,532	Telephone	302-992-2368
Signature				Date	6 December 2001

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN THE APPLICATION OF:

Priestley et al

CASE NO.:

PH-7087-A

SERIAL NO.:

Unknown

FILING DATE:

December 6, 2001

GROUP NUMBER:

1653

EXAMINER:

D. LUKTON

FOR: NOVEL LACTAM INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE

Assistant Commissioner for Patents

Washington, DC 20231

**SUBMISSION OF SEQUENCE LISTING & COMPUTER READABLE COPY FOR
INVENTION CONTAINING AMINO ACID SEQUENCE**


Sir:

Submitted herewith is/are:

- A. "Sequence Listing(s)" for the nucleotide and/or amino acid sequence(s) in this application. Each "Sequence Listing" is assigned a separate identifier as required in 37 C.F.R. §1.821(c) and 37 C.F.R. § 1.822 and 1.823.
- B. A copy of each "Sequence Listing" submitted for this application in computer readable form, in accordance with the requirements of 37 CFR §§ 1.821(e) and 1.824.
- C. A statement that the content of each "Sequence Listing" submitted and each computer readable copy are the same, as required in 37 C.F.R. § 1.821(g).

I hereby state that the information recorded in computer readable form is identical to the written sequence enclosed herein, respectively, and that the Listing does not introduce any new matter.

Respectfully submitted,



Scott K. Larsen
Attorney for Applicants
Registration No. 38,532
Telephone: (302) 922-2368

Dated: *Dec 6, 2001*

EXPRESS MAIL: EV000875667US -
MAILED: December 6, 2001